GDF-15 and Early Outcomes After LVAD Implantation
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAkdeniz University
About this trial
This observational study aims to investigate the association between preoperative GDF-15 levels and early postoperative outcomes in patients undergoing left ventricular assist device (LVAD) implantation. The study will evaluate whether elevated preoperative GDF-15 levels are associated with adverse early outcomes, including postoperative complications and mortality. The findings may help improve preoperative risk assessment and identify high-risk patients before LVAD implantation.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
The study population consists of adult patients with advanced heart failure undergoing LVAD implantation. Eligible participants are those with available preoperative GDF-15 measurements who meet the study inclusion and exclusion criteria.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
48 Participants
are grouped into 1 trial groupGroup A: Patients Undergoing LVAD Implantation
Trial outcomes
Primary outcomes
1
Early Postoperative Mortality
Mortality occurring during the early postoperative period after LVAD implantation
Time frame
30 days after LVAD implantationSecondary outcomes
1
Postoperative Complications
Occurrence of early postoperative complications after LVAD implantatio
Time frame
Up to 30 days after LVAD implantationSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov